Treatment of mice after HCC development with 3′3′-cAIMP, a cyclic dinucleotide STING agonist, effectively reduces the tumor size in cGAS–/– mice, which cannot generate 2′3′-cGAMP (Thomsen et al., 2020). The gene discussed is STING1; the disease is hepatocellular carcinoma.